Drugs / GSK2189242A
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00707798 | Jun 2008 → Jan 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT01545375 | May 2012 → Jul 2016 | streptococcal infection | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT01262872 | Feb 2011 → Mar 2013 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01204658 | Sep 2010 → Nov 2011 | streptococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 2 | NCT00985751 | Nov 2009 → Oct 2010 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00896064 | May → Aug 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK 2189242A | “pneumococcal vaccines (GSK 2189242A)” NCT00896064 ↗ |
| Known as | 10PP | “This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with low doses...” NCT01204658 ↗ |
| Known as | dPly-PhtD | “receiving GSK2189242A (dPly-PhtD) vaccine co-administered with Prevenar13™” NCT01545375 ↗ |
| Modality | Vaccine | “novel pneumococcal protein-based vaccine” PMID 24607003 ↗ Mar 2014 |
| Route | Intramuscular | “administered intramuscularly” NCT00707798 ↗ |